About
Antibody Mimetics
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibody
Team (14)
Clinical Trials (9)
View allTotal Trials
9
As Lead Sponsor
5
As Collaborator
4
Total Enrollment
571
By Phase
PHASE1: 4PHASE2: 3NA: 1PHASE1/PHASE2: 1
By Status
COMPLETED: 4RECRUITING: 2TERMINATED: 2NOT_YET_RECRUITING: 1
Clinical Trials Pipeline9 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
Today
Hover over trial bars to see details
Recent Trials
NCT07081555Lead Sponsor
A First-in-Human Phase 1 Safety and Biodistribution of [177Lu]Lu-ABY-271 in Subjects With HER2-positive Metastatic Breast Cancer
PHASE1Recruiting
21 participants
Started: Oct 6, 2025 · Completed: Jun 1, 2028
NCT06830382Collaborator
HER2-PET as a Precision Imaging Tool for Treatment With HER2-ADC in HER2-expressing mBC
PHASE2Not yet recruiting
70 participants
Started: Apr 1, 2025 · Completed: Apr 1, 2032
NCT04795141Collaborator
ABY-035 in the Treatment of Subjects With Ankylosing Spondylitis
PHASE2Terminated
25 participants
Started: Aug 24, 2021 · Completed: Aug 30, 2022
NCT03580278Lead Sponsor
A Study to Investigate the Safety, Tolerability, Pharmacokinetic, and Efficacy of ABY-035/AFO2
PHASE1Completed
33 participants
Started: Nov 13, 2019 · Completed: Sep 22, 2020
NCT03655353Collaborator
A Study of 68Ga-ABY-025 PET for Non-invasive Quantification of HER2-expression in Advanced Breast Cancer
NARecruiting
160 participants
Started: Aug 22, 2018 · Completed: Nov 1, 2025
Locations (1)
Headquarters
Solna, Sweden
Map
Loading map...